Nutcracker Therapeutics and Elegen initiated a pilot for a fully synthetic, cell-free manufacturing platform to produce RNA-based personalized cancer therapeutics (PCTs). The platform addresses limitations of traditional production reliant on bacterial cells and slow, inefficient RNA synthesis, reducing contamination risks, timelines to three weeks, and costs. This scalable approach aims to democratize PCT access, accelerating treatment availability and improving outcomes for patients requiring individualized therapies.